Decreased glutathione levels and impaired antioxidant enzyme activities in drug-naive first-episode schizophrenic patients.
about
A review of anti-inflammatory agents for symptoms of schizophreniaMolecular substrates of schizophrenia: homeostatic signaling to connectivityReduction in phencyclidine induced sensorimotor gating deficits in the rat following increased system xc⁻ activity in the medial prefrontal cortex.Oxidative stress and schizophrenia: recent breakthroughs from an old storyGeneration of superoxide anion radicals and platelet glutathione peroxidase activity in patients with schizophrenia.Meta-analysis of oxidative stress in schizophrenia.Erythrocyte glutathione levels as long-term predictor of transition to psychosisElectrophysiological intermediate biomarkers for oxidative stress in schizophreniaPolyphenols from Berries of Aronia melanocarpa Reduce the Plasma Lipid Peroxidation Induced by Ziprasidone.Age-dependent decrease and alternative splicing of methionine synthase mRNA in human cerebral cortex and an accelerated decrease in autismOxidative stress and level of antioxidant enzymes in drug-naive schizophrenics.The promise of biological markers for treatment response in first-episode psychosis: a systematic review.Role of nitric oxide and related molecules in schizophrenia pathogenesis: biochemical, genetic and clinical aspects.Comparative Study on Serum Levels of 10 Trace Elements in SchizophreniaNOX2 As a Target for Drug Development: Indications, Possible Complications, and Progress.Antioxidants as potential therapeutics for neuropsychiatric disorders.No evidence of exogenous origin for the abnormal glutathione redox state in schizophrenia.Decreased zinc availability affects glutathione metabolism in neuronal cells and in the developing brain.Proteomic profiling in schizophrenia: enabling stratification for more effective treatment.A randomized placebo-controlled trial of an omega-3 fatty acid and vitamins E+C in schizophrenia.Long-Term Effects of Maternal Deprivation on Redox Regulation in Rat Brain: Involvement of NADPH Oxidase.Glutamate drugs and pharmacogenetics of OCD: a pathway-based exploratory approach.Oxidative stress, prefrontal cortex hypomyelination and cognitive symptoms in schizophreniaReduction of plasma glutathione in psychosis associated with schizophrenia and bipolar disorder in translational psychiatryGenetic Polymorphism Associated Prefrontal Glutathione and Its Coupling With Brain Glutamate and Peripheral Redox Status in Early PsychosisFirst-episode psychosis is associated with oxidative stress: Effects of short-term antipsychotic treatment.Supplemental lipoic acid relieves post-weaning diarrhoea by decreasing intestinal permeability in rats.A three-month longitudinal study of changes in day/night serum total antioxidant capacity in paranoid schizophrenia.Peripheral levels of superoxide dismutase and glutathione peroxidase in youths in ultra-high risk for psychosis: a pilot study.Effects of omega-3 supplementation on interleukin and neurotrophin levels in an animal model of schizophrenia.Thiol Disulfide Homeostasis in Schizophrenic Patients Using Atypical Antipsychotic Drugs.Day/Night and Summer/Winter Changes in Serum Total Antioxidant Capacity.Serum Glutathione in Patients with Schizophrenia in Dynamics of Antipsychotic Therapy.GC-MS based metabolomics identification of possible novel biomarkers for schizophrenia in peripheral blood mononuclear cells.The complex association between the antioxidant defense system and clinical status in early psychosis.Glutathione, the Major Redox Regulator, in the Prefrontal Cortex of Individuals at Clinical High Risk for Psychosis.Nicorandil reverses the behavioral changes and brain oxidative stress in a model of schizophrenia induced by ketamine in mice
P2860
Q22241827-63D0E68F-2F92-45C5-B814-F0072BE42DC4Q30383611-DD96CD64-6943-4389-AEF5-24C5DC768A2FQ30440988-94AEAC48-E76B-44E6-B8F4-5EB7208A2FCBQ30774039-9F58E1BA-4005-4595-989C-FB0FA2C01863Q33589462-AA04C042-1906-4059-A97B-912B42FC1DE6Q33601360-337E1BC2-9C6D-4760-B210-0B2F847510BBQ33635566-EA867310-C499-4C10-904D-B9012D670DD9Q33647885-4C386586-B889-473C-AD0F-6E65EE7B2897Q33904833-66EA8428-76D5-4B8D-A247-65027915E318Q34599738-83D92C93-FD93-4861-9665-001C8FD6C362Q34786239-BC7F4126-354B-496F-9967-38CB891784BDQ35369988-08D559EF-4B87-4C88-BE40-766CE1367609Q35591134-0E3E338E-09F9-409A-94D4-80B93B4BA0FFQ35694385-C71DF5BC-A87E-4B40-915C-0EE67C95BDA7Q35985407-B8FB6F39-FB39-4ED2-941C-83E6A23A71FEQ36736055-D82DB3A0-43D9-4D0C-9D41-9B7DE6DB0364Q36756178-DDC37C83-D41A-4DF2-AAB3-189076817F12Q36769345-05C67B93-67E2-45BB-A8E0-9B9E11AFAD7DQ36998471-154CAED0-6F2C-4158-8B48-B1992039EF9CQ37530729-783F64D2-360B-4800-8127-0E9B4DF47898Q37734352-116E4FDA-08A4-483A-A5DC-7D72F41B8DE4Q38154625-86823BA2-B56A-469F-8D7D-5CB805293507Q41197010-2057C85A-8041-42C8-84C5-7EE75B27D9B0Q41687474-FE913A7D-0817-4AC3-AFD7-6C73F80CFB9BQ41703320-14DD1EB2-64C7-4A2C-907A-CAD9790E22E4Q42479721-E84046A3-E3C3-4F20-9B5C-A81DFDF10F9AQ42486880-AEF8F16A-A045-4CBE-9FE4-EBEC21DD1DB6Q47093804-FB840E99-718F-4A2A-88D2-0B8C8E70A191Q47297974-317B3D6E-B08F-4A48-ACEB-D28D1544CA8BQ47649451-3FC361AD-92B9-4907-AB8E-636B15EE4D25Q49348765-76AFD3E5-2446-45F1-8AAF-05155EE0B6E5Q50263200-374CCD1F-CF0E-420E-B5A4-790B89464248Q50552178-085A4166-029D-40F4-8F7A-5F4A2E3C51EDQ50635567-F14727FA-134F-4321-8BA9-E50C5102DCECQ52308849-42226147-DA8B-462A-B419-D77FF79FB46CQ55262427-5AF06E8B-DC34-493E-A0A0-566648268BDAQ57729831-F6D86E06-E086-41E7-BEB7-76B4E7F62933
P2860
Decreased glutathione levels and impaired antioxidant enzyme activities in drug-naive first-episode schizophrenic patients.
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Decreased glutathione levels a ...... pisode schizophrenic patients.
@ast
Decreased glutathione levels a ...... pisode schizophrenic patients.
@en
type
label
Decreased glutathione levels a ...... pisode schizophrenic patients.
@ast
Decreased glutathione levels a ...... pisode schizophrenic patients.
@en
prefLabel
Decreased glutathione levels a ...... pisode schizophrenic patients.
@ast
Decreased glutathione levels a ...... pisode schizophrenic patients.
@en
P2093
P2860
P356
P1433
P1476
Decreased glutathione levels a ...... pisode schizophrenic patients.
@en
P2093
Abdelhamid Kerkeni
Ahmed Mhalla
Anwar Mechri
Fatma Atig
Monia Raffa
P2860
P2888
P356
10.1186/1471-244X-11-124
P577
2011-08-02T00:00:00Z
P6179
1037723913